Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 720858, 7 pages
http://dx.doi.org/10.1155/2013/720858
Review Article

Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent

1Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium
2Laboratory of Experimental Surgery, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium

Received 31 January 2013; Accepted 26 February 2013

Academic Editors: K. Aoyagi, H. C. Lien, L. Roncucci, and T. K. Ti

Copyright © 2013 L. De Smet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Koppe, O. C. Boerman, W. J. G. Oyen, and R. P. Bleichrodt, “Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies,” Annals of Surgery, vol. 243, no. 2, pp. 212–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Sadeghi, C. Arvieux, O. Glehen et al., “Peritoneal carcinomatosis from non-gynecologic malignancies—results of the EVOCAPE 1 multicentric prospective study,” Cancer, vol. 88, pp. 358–363, 2000. View at Google Scholar
  4. W. Scheithauer, H. Rosen, G. V. Kornek, C. Sebesta, and D. Depisch, “Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer,” British Medical Journal, vol. 306, no. 6880, pp. 752–755, 1993. View at Google Scholar · View at Scopus
  5. T. André, C. Boni, L. Mounedji-Boudiaf et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. de Gramont, A. Figer, M. Seymour et al., “Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 2938–2947, 2000. View at Google Scholar · View at Scopus
  7. J. Cassidy, S. Clarke, E. Díaz-Rubio et al., “Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2006–2012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Porschen, H. T. Arkenau, S. Kubicka et al., “Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group,” Journal of Clinical Oncology, vol. 25, no. 27, pp. 4217–4223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. S. Spratt, R. A. Adcock, and M. Muskovin, “Clinical delivery system for intraperitoneal hyperthermic chemotherapy,” Cancer Research, vol. 40, no. 2, pp. 256–260, 1980. View at Google Scholar · View at Scopus
  10. P. E. Colombo, M. Boustta, S. Poujol et al., “Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer,” Gynecologic Oncology, vol. 122, pp. 632–640, 2011. View at Google Scholar
  11. V. J. Verwaal, S. van Ruth, E. de Bree et al., “Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3737–3743, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Elias, F. Gilly, F. Quenet et al., “Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy,” European Journal of Surgical Oncology, vol. 36, no. 5, pp. 456–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Speyer and C. E. Myers, “The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies,” Recent Results in Cancer Research, vol. 74, pp. 264–269, 1980. View at Google Scholar · View at Scopus
  14. S. Koga, R. Hamazoe, M. Maeta, N. Shimizu, A. Murakami, and T. Wakatsuki, “Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C,” Cancer, vol. 61, no. 2, pp. 232–237, 1988. View at Google Scholar · View at Scopus
  15. Y. L. B. Klaver, T. Hendriks, R. Lomme et al., “Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study,” Annals of Surgical Oncology, vol. 19, supplement 3, pp. S475–S482, 2012. View at Publisher · View at Google Scholar
  16. F. Aarts, R. P. Bleichrodt, B. de Man, R. Lomme, O. C. Boerman, and T. Hendriks, “The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat,” Annals of Surgical Oncology, vol. 15, no. 11, pp. 3299–3307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Elias, F. Blot, A. El Otmany et al., “Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy,” Cancer, vol. 92, pp. 71–76, 2001. View at Google Scholar
  18. J Esquivel, P. H. Sugarbaker, and C. W. Helm, Techniques of Delivering Hyperthermic Intraperitoneal Chemotherapy, Humana Press, Totowa, NJ, USA, 2007.
  19. O. Glehen, F. Mohamed, and F. N. Gilly, “Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia,” Lancet Oncology, vol. 5, no. 4, pp. 219–228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Zeamari, B. Floot, N. Van der Vange, and F. A. Stewart, “Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC),” Anticancer Research, vol. 23, no. 2, pp. 1643–1648, 2003. View at Google Scholar · View at Scopus
  21. V. J. Verwaal, S. Bruin, H. Boot, G. van Slooten, and H. van Tinteren, “8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer,” Annals of Surgical Oncology, vol. 15, no. 9, pp. 2426–2432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Hirano, C. A. Hunt, A. Strubbe, and R. D. MacGregor, “Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration. Effect of lipid composition,” Pharmaceutical Research, vol. 6, pp. 271–278, 1985. View at Google Scholar · View at Scopus
  23. R. L. Dedrick, C. E. Myers, P. M. Bungay, and V. T. Devita, “Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer,” Cancer Treatment Reports, vol. 62, no. 1, pp. 1–11, 1978. View at Google Scholar · View at Scopus
  24. K. Fujiwara, D. Armstrong, M. Morgan, and M. Markman, “Principles and practice of intraperitoneal chemotherapy for ovarian cancer,” International Journal of Gynecological Cancer, vol. 17, no. 1, pp. 1–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. D. K. Armstrong and M. F. Brady, “Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4531–4533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Tamura, J. Imai, A. Matsumoto et al., “Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 54, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Fujiyama, Y. Nakase, K. Osaki, C. Sakakura, H. Yamagishi, and A. Hagiwara, “Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application,” Journal of Controlled Release, vol. 89, no. 3, pp. 397–408, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Lu, M. Tsai, D. Lu, J. Wang, M. G. Wientjes, and J. L. S. Au, “Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 3, pp. 673–682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. K. Armstrong, G. F. Fleming, M. Markman, and H. H. Bailey, “A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 103, no. 2, pp. 391–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Dai, X. Xu, J. Song et al., “Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice,” Cancer Letters, vol. 312, pp. 189–196, 2011. View at Google Scholar
  31. D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. D. S. Kohane, J. Y. Tse, Y. Yeo, R. Padera, M. Shubina, and R. Langer, “Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum,” Journal of Biomedical Materials Research A, vol. 77, no. 2, pp. 351–361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Bennis, C. Chapey, P. Couvreur, and J. Robert, “Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture,” European Journal of Cancer A, vol. 30, no. 1, pp. 89–93, 1994. View at Google Scholar · View at Scopus
  34. D. Sadava, A. Coleman, and S. E. Kane, “Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells,” Journal of Liposome Research, vol. 12, no. 4, pp. 301–309, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. L. Colson, R. Liu, E. B. Southard et al., “The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis,” Biomaterials, vol. 32, no. 3, pp. 832–840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Dadashzadeh, N. Mirahmadi, M. H. Babaei, and A. M. Vali, “Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge,” Journal of Controlled Release, vol. 148, no. 2, pp. 177–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Sadzuka, S. Hirota, and T. Sonobe, “Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination,” Toxicology Letters, vol. 116, no. 1-2, pp. 51–59, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Gelderblom, J. Verweij, D. M. van Zomeren et al., “Influence of cremophor EL on the bioavailability of intraperitoneal paclitaxel,” Clinical Cancer Research, vol. 8, no. 4, pp. 1237–1241, 2002. View at Google Scholar · View at Scopus
  39. R. B. Weiss, R. C. Donehower, P. H. Wiernik et al., “Hypersensitivity reactions from taxol,” Journal of Clinical Oncology, vol. 8, no. 7, pp. 1263–1268, 1990. View at Google Scholar · View at Scopus
  40. L. De Smet, P. Colin, W. Ceelen et al., “Development of a nanocrystalline paclitaxel formulation for hipec treatment,” Pharmaceutical Research, vol. 29, pp. 2398–2406, 2012. View at Google Scholar
  41. M. Tsai, Z. Lu, J. Wang, T. K. Yeh, M. G. Wientjes, and J. L. S. Au, “Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel,” Pharmaceutical Research, vol. 24, no. 9, pp. 1691–1701, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Yokogawa, M. Jin, N. Furui et al., “Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles,” Journal of Pharmacy and Pharmacology, vol. 56, no. 5, pp. 629–634, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Zahedi, J. Stewart, R. De Souza et al., “An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels,” Journal of Controlled Release, vol. 158, pp. 379–385, 2012. View at Google Scholar
  44. Y. Yeo, T. Ito, E. Bellas, C. B. Highley, R. Marini, and D. S. Kohane, “In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions,” Annals of Surgery, vol. 245, no. 5, pp. 819–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Xie, Q. D. Long, Q. J. Wu et al., “Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite,” RSC Advances, vol. 2, pp. 7759–7771, 2012. View at Google Scholar
  46. J. Y. Lee, K. S. Kim, Y. M. Kang et al., “In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth,” International Journal of Pharmaceutics, vol. 392, no. 1-2, pp. 51–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. S. Wang, C. Y. Gong, L. Yang et al., “5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice,” BMC Cancer, vol. 10, article 402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Y. Gong, B. Yang, Z. Y. Qian et al., “Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles,” Nanomedicine-Nanotechnology Biology and Medicine, vol. 8, pp. 963–973, 2012. View at Google Scholar
  49. P. L. Soo, J. Cho, J. Grant, E. Ho, M. Piquette-Miller, and C. Allen, “Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 1, pp. 149–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Grant, M. Blicker, M. Piquette-Miller, and C. Allen, “Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel,” Journal of Pharmaceutical Sciences, vol. 94, no. 7, pp. 1512–1527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Rosenshein, D. Blake, and P. A. McIntyre, “The effect of volume on the distribution of substances instilled into the peritoneal cavity,” Gynecologic Oncology, vol. 6, no. 1, pp. 106–110, 1978. View at Google Scholar · View at Scopus
  52. S. R. Pestieau, K. J. Schnake, O. A. Stuart, and P. H. Sugarbaker, “Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 3, pp. 269–276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kusamura, E. Dominique, D. Baratti, R. Younan, and M. Deraco, “Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy,” Journal of Surgical Oncology, vol. 98, no. 4, pp. 247–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. I. J. Torres, C. L. Litterst, and A. M. Guarino, “Transport of model compounds across the peritoneal membrane in the rat,” Pharmacology, vol. 17, no. 6, pp. 330–340, 1978. View at Google Scholar · View at Scopus
  55. S. Tsujitani, A. Oka, A. Kondo et al., “Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats,” Oncology, vol. 57, no. 1, pp. 77–82, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Elias, A. El Otmany, M. Bonnay et al., “Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis,” Oncology, vol. 63, no. 4, pp. 346–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Tsujitani, K. Fukuda, H. Saito et al., “The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer,” Surgery, vol. 131, no. 1, supplement 1, pp. S98–S104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Hosie, J. A. Gilbert, D. Kerr, C. B. Brown, and E. M. Peers, “Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin,” Drug Delivery, vol. 8, no. 1, pp. 9–12, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Mohamed, P. Marchettini, O. A. Stuart, and P. H. Sugarbaker, “Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 5, pp. 405–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. G. Wei, G. X. Li, X. C. Huang et al., “Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats,” World Journal of Gastroenterology, vol. 14, no. 14, pp. 2179–2186, 2008. View at Publisher · View at Google Scholar · View at Scopus